Recombinant erythropoietin biosimilar (Biogenomics)

重组促红细胞生成素生物类似药 (Biogenomics)

Report date: 2025/05/06 15:48:41

Base Information

Drug NameRecombinant erythropoietin biosimilar (Biogenomics)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiogenomics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogenomics
Active IndicationsN/A
Inactive IndicationsAnemia

Other Information

ATC CodeN/A
Related LinksN/A